<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426695</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2066</org_study_id>
    <secondary_id>2020-002537-15</secondary_id>
    <nct_id>NCT04426695</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19</brief_title>
  <official_title>A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are:

      Phase 1

        -  To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo

        -  To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in
           reducing viral shedding of SARS-CoV-2 Phase 2

        -  To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in
           reducing viral shedding of SARS-CoV-2

        -  To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo in
           improving clinical status Phase 3

        -  To evaluate and confirm the clinical efficacy of REGN10933+REGN10987 compared to placebo
           in improving clinical status
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">January 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1/Phase 2/Phase 3</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Primary:
Up to Day 169: Phase 1: C1
Secondary:
Up to Day 29: Phase 1: C1, Phase 2: C1A, C1, C2, C3 Up to Day 57: Phase 2: C1A, C1, C2, C3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with infusion-related reactions</measure>
    <time_frame>Through Day 4</time_frame>
    <description>Primary: Phase 1:C1 Secondary: Phase 2: C1A, C1, C2, C3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with hypersensitivity reactions</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Primary: Phase 1:C1 Secondary: Phase 2: C1A, C1, C2, C3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1:C1 Phase 2: C1A, C1, C2, C3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with at least 1-point improvement on a 7-Point Ordinal Scale in clinical status</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Primary:
Day 8: Phase 2: C1A, C1, Phase 3:C1 Day 22: Phase 2:C2, C3, Phase 3:C2, C3
Secondary:
Day 8: Phase 1:C1 Day 29: Phase 1:C1, Phase 2: C1A, C1, C2, C3
7-point Ordinal Scale:
Death;
Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
Hospitalized, requiring non-invasive ventilation or high flow oxygen devices;
Hospitalized, requiring supplemental oxygen;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
Not hospitalized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in nasal samples</measure>
    <time_frame>Baseline up to Day 22</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in NP swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted average change in viral shedding</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in saliva samples</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs</measure>
    <time_frame>Baseline up to Day 29</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of RT-qPCR results over time between different sample types</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of RT-qPCR results over time between different sample types</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1: C1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least 2-point improvement on a 7-Point Ordinal Scale in clinical status</measure>
    <time_frame>From Day 1 up to Day 29</time_frame>
    <description>Phase 1: C1, Phase 2: C1A, C1 Day 8
Phase 2: C2, C3 Day 22
Phase 1: C1, Phase 2: C1A, C1, C2, C3 Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to no longer requiring oxygen supplementation</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of supplemental oxygen use</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients initiating high-intensity oxygen therapy</measure>
    <time_frame>Up to Day 29 or hospital discharge</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of high-intensity oxygen therapy</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients initiating mechanical ventilation</measure>
    <time_frame>Up to Day 29 or hospital discharge</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of mechanical ventilation</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator-free days</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients re-admitted to hospital after discharge through the end of study</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients admitted into an intensive care unit (ICU)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of ICU stay</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 1: C1 Phase 2: C1A, C1, C2, C3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths due to any cause (All-Cause Mortality)</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1 Through Day 29 and Day 169
Phase 2: C1A, C1, C2, C3 Through Day 29 and Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 57</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN10933 over time</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN10987 over time</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1: C1:
Through Day 169
Phase 2: C1A, C1, C2, C3:
Through Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933</measure>
    <time_frame>Through day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987</measure>
    <time_frame>Through day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Time to Cmax (tmax) for REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Clearance (CL) for REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Clearance (CL) of REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Mean residence time (MRT) of REGN10933</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Mean residence time (MRT) of REGN10987</measure>
    <time_frame>Through Day 169</time_frame>
    <description>Phase 1 only</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2970</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>On Low-Flow Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 (C1): O2 saturation &gt;93% on low-flow oxygen via nasal cannula, simple face mask, or other similar device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>With COVID-19 symptoms but not requiring supplemental O2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1A (C1A): With COVID-19 symptoms but not requiring supplemental oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High O2 No Mechanical Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 (C2): On high-intensity oxygen (O2) therapy but not on mechanical ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>On Mechanical Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 (C3): On mechanical ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN10933+REGN10987 combination therapy</intervention_name>
    <description>Administered intravenously (IV) single dose</description>
    <arm_group_label>High O2 No Mechanical Ventilation</arm_group_label>
    <arm_group_label>On Low-Flow Oxygen</arm_group_label>
    <arm_group_label>On Mechanical Ventilation</arm_group_label>
    <arm_group_label>With COVID-19 symptoms but not requiring supplemental O2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV Single Dose</description>
    <arm_group_label>High O2 No Mechanical Ventilation</arm_group_label>
    <arm_group_label>On Low-Flow Oxygen</arm_group_label>
    <arm_group_label>On Mechanical Ventilation</arm_group_label>
    <arm_group_label>With COVID-19 symptoms but not requiring supplemental O2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Has SARS-CoV-2-positive antigen or molecular diagnostic test (by validated SARS-CoV-2
             antigen, RT-PCR, or other molecular diagnostic assay, using an appropriate sample such
             as NP, nasal, oropharyngeal [OP], or saliva) ≤72 hours prior to randomization and no
             alternative explanation for current clinical condition. A historical record of
             positive result from test conducted ≤72 hours prior to randomization is acceptable.

          -  Has symptoms consistent with COVID-19, as determined by investigator, with onset ≤10
             days before randomization

          -  Hospitalized for COVID-19 illness for ≤72 hours with at least 1 of the following at
             randomization; patients meeting more than one criterion will be categorized in the
             most severely affected category:

               1. Cohort 1A: With COVID-19 symptoms but not requiring supplemental oxygen

               2. Cohort 1: Maintains O2 saturation &gt;93% on low-flow oxygen as defined in the
                  protocol

               3. Cohort 2: High-intensity oxygen therapy without mechanical ventilation as defined
                  in the protocol

               4. Cohort 3: On mechanical ventilation

        Key Exclusion Criteria:

          -  Phase 1 Only: Patients maintaining O2 saturation &gt;94% on room air

          -  In the opinion of the investigator, unlikely to survive for &gt;48 hours from screening

          -  Receiving extracorporeal membrane oxygenation (ECMO)

          -  Has new-onset stroke or seizure disorder during hospitalization

          -  Initiated on renal replacement therapy due to COVID-19

        NOTE: Other protocol defined inclusion / exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>West Islip</city>
        <state>New York</state>
        <zip>11795</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>coronavirus</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

